Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Niraparib (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms NiraRad
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.
- 25 Jul 2017 Planned initiation date changed from 1 May 2017 to 1 May 2018.
- 14 Mar 2017 New trial record